Organization
Pharmacovigilance, BioCryst Pharmaceuticals, Inc., Durham, NC
1 abstract
Abstract
BCX4208, A NOVEL URATE-LOWERING THERAPY, WAS GENERALLY SAFE AND WELL TOLERATED IN TWO 3-WEEK STUDIES IN GOUT SUBJECTS Org: Pharmacovigilance, BioCryst Pharmaceuticals, Inc., Durham, NC, Biostatistics, PharPoint Research Inc., Chapel Hill, NC, Pharmacology Discovery Services Taiwan, Ltd., Clinical Development, BioCryst Pharmaceuticals, Inc., Durham, NC, United States,